[High-frequency oscillatory lung ventilation in complex therapy for congenital pneumonia and hyaline membrane disease in newborns].
Fifty-eight neonatal infants with hyaline membrane disease (HMD) and congenital pneumonia were examined in the critical status. In 32 of them, high-frequency oscillatory lung ventilation (HFOLV) was employed. The use of HFOLV was found to reduce the length of stay in neonates on toxic oxygen concentrations by more than 2 times and to accelerate the normalization of ventilation-perfusion relationships by more than 3 times. A study of the basic parameters of central and regional hemodynamics showed that HFOLV failed to affect the patients' hemodynamic status. The efficiency of correction of severe respiratory disorders in neonatal infants with HMD was ascertained to increase with the combined use of the Russian surfactant and HFOLV. A formula was developed to calculate the starting amplitude of oscillations when HFOLV was employed. The maximum allowable values of mean airway pressure at which HFOLV could be discontinued were determined, which prevented the regimens from toughening when HFOLV was changed to the routine artificial ventilation. The use of HFOLV was established to reduce the risk of severe cerebral structural and vascular lesions and mortality rates.
Antonov
A G
AG
Ionov
O V
OV
Burkova
A S
AS
D001034:Apgar Score; D001724:Birth Weight; D001784:Blood Gas Analysis; D005865:Gestational Age; D006439:Hemodynamics / Q000502:physiology; D006612:High-Frequency Ventilation / Q000379:methods*; D006801:Humans; D006819:Hyaline Membrane Disease / Q000503:physiopathology / Q000628:therapy*; D007231:Infant, Newborn; D011014:Pneumonia / Q000151:congenital* / Q000503:physiopathology / Q000628:therapy*; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*
D011663:Pulmonary Surfactants